Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Am J Cancer Res
Κύριοι συγγραφείς: Fernández, Marta Llauradó, DiMattia, Gabriel E, Dawson, Amy, Bamford, Sylvia, Anderson, Shawn, Hennessy, Bryan T, Anglesio, Michael S, Shepherd, Trevor G, Salamanca, Clara, Hoenisch, Josh, Tinker, Anna, Huntsman, David G, Carey, Mark S
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: e-Century Publishing Corporation 2016
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/
https://ncbi.nlm.nih.gov/pubmed/27822414
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια